Literature DB >> 9725246

Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.

G P Bembridge1, R Garcia-Beato, J A López, J A Melero, G Taylor.   

Abstract

The attachment glycoprotein (G) of respiratory syncytial virus (RSV) is synthesized as two mature forms: a membrane-anchored form and a smaller secreted form. Mutant cDNAs were constructed that encoded one or the other form of the protein and were expressed in recombinant vaccinia viruses (rVV). Mice were immunized with rVV by dermal scarification or i.p. injection to determine the contribution of the membrane-anchored and secreted forms of the G protein on the augmentation of pulmonary pathology seen following RSV challenge. Mice scarified with rVV expressing the membrane-anchored G protein had a markedly reduced pulmonary eosinophilic response following RSV challenge compared with mice scarified with rVV expressing either wild-type or secreted G protein. The induction of pulmonary eosinophilia in rVV-primed mice was also dependent upon the route of vaccination. An eosinophilic response was not observed in any groups of mice immunized i.p. with rVV expressing any of the different forms of the G protein. The difference in pulmonary pathology observed between dermal scarification or i.p. vaccinated mice was not reflected in a difference in cytokine production by splenocytes from vaccinated and challenged mice restimulated with RSV in vitro. Both groups produced significant levels of IL-4 and IL-5. These data suggest that the local APCs and lymphoid environment, together with the form of the G protein, influence pulmonary pathology following RSV challenge.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725246

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.

Authors:  R A Tripp; D Moore; J Winter; L J Anderson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

5.  Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.

Authors:  G P Bembridge; J A Lopez; R Bustos; J A Melero; R Cook; H Mason; G Taylor
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 6.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

7.  Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Michael N Teng; Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus.

Authors:  Elaine M Castilow; Matthew R Olson; David K Meyerholz; Steven M Varga
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

9.  Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.

Authors:  Jae-Rang Yu; Sol Kim; Jee-Boong Lee; Jun Chang
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

10.  Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Steven M Varga; Thomas J Braciale; Barney S Graham
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.